GLP-1 drugs and fewer knee replacements

A retrospective analysis of more than 42,000 propensity-matched patients estimates that widespread use of GLP-1 receptor agonists could translate to roughly 14,400 fewer total knee replacements per year in the United States alone^[1]. The study, published on 2 June 2026 in Regional Anesthesia and Pain Medicine, found that patients on semaglutide or tirzepatide for at least three years had a 28% lower risk of needing surgery for knee osteoarthritis compared with matched non-users.

How the researchers arrived at 14,400

Victoria Carter and colleagues drew on the TriNetX Global Research Network, a database of anonymised medical records spanning 2010 to 2024. They identified adults diagnosed with knee osteoarthritis, stratified them by GLP-1 receptor agonist exposure type and duration, then compared each group with propensity-score-matched controls. The matching balanced age, sex, BMI, diabetes status, and other confounders^[1].

At one year of any GLP-1 receptor agonist use, the hazard ratio for total knee arthroplasty was 0.90 (95% CI 0.83 to 0.98), corresponding to an absolute risk difference of 2.80 percentage points at eight years of follow-up. When the analysis was restricted to three or more years on semaglutide or tirzepatide specifically, the hazard ratio dropped to 0.72 (95% CI 0.67 to 0.78), with an absolute risk difference of 4.71 percentage points^[1]. The 14,400 figure comes from applying the one-year absolute risk reduction of 1.44% across the estimated population of US knee-OA patients currently eligible for GLP-1 therapy.

Weight loss, inflammation, or both

The most straightforward explanation is mechanical unloading. Excess body weight is the single largest modifiable risk factor for knee osteoarthritis, and each kilogram of body mass adds roughly four kilograms of force across the joint during walking. Over years, that cumulative load accelerates cartilage degradation. GLP-1 receptor agonists produce sustained weight reductions of 15 to 21% in Phase 3 trials, which for an average participant translates to 15 to 25 kilograms of lost mass and a corresponding drop in joint loading with every step.

But the Carter study observed a larger effect with newer dual-agonist agents and with longer treatment duration, which the authors say is consistent with "potential disease modifying activity beyond weight loss alone"^[1]. Laboratory work has identified GLP-1 receptors on chondrocytes, the cells that maintain cartilage, and preclinical models suggest that GLP-1 signalling may dampen inflammatory cytokines involved in cartilage breakdown. Systemic inflammation is itself a recognised driver of osteoarthritis progression, independent of mechanical load. The hypothesis has biological plausibility, but no clinical trial has isolated the anti-inflammatory contribution from the weight-loss contribution in humans.

What the study cannot tell us

This is a retrospective database study, not a randomised controlled trial. Propensity-score matching reduces measured confounding but cannot eliminate selection bias entirely. Patients prescribed GLP-1 receptor agonists tend to have better healthcare access and more regular clinical contact, which could itself reduce progression to surgery through earlier non-surgical treatment. The TriNetX records also lack standardised imaging and consistent coding of osteoarthritis severity^[1].

A separate Taiwanese cohort of 35,762 patients with type-2 diabetes reached a compatible but smaller estimate: GLP-1 receptor agonist therapy was associated with a reduced risk of both knee osteoarthritis (adjusted HR 0.85, 95% CI 0.78 to 0.93) and total knee replacement (adjusted HR 0.91, 95% CI 0.89 to 0.98)^[2]. The directional agreement across two independent databases in different populations strengthens the signal, but both teams stress the same point: prospective randomised trials are needed before anyone can claim a causal protective effect.

What this means for readers

If you are already on a GLP-1 receptor agonist for diabetes or weight management, this evidence suggests joint health may be an additional long-term benefit worth discussing with your prescriber. It does not, by itself, justify starting a GLP-1 drug specifically for osteoarthritis. No regulator has approved any drug in this class for joint protection, and no clinical practice guideline recommends it for that purpose.

The 14,400 projection is a useful number for thinking about scale. Total knee arthroplasty is one of the most common elective surgeries performed in the United States, with roughly one million procedures each year. If confirmed, even a modest absolute risk reduction across a large eligible population adds up to a meaningful decrease in surgical volume, recovery burden, and healthcare spending. That is the population-level case for paying attention to this data.

For country-specific prescribing rules, see the semaglutide regulation pages and the tirzepatide regulation pages. For questions about whether a GLP-1 receptor agonist is appropriate for your situation, consult a clinician who knows your history.